Your browser doesn't support javascript.
loading
[Klinefelter's syndrome diagnosed at the onset of acute myeloid leukemia with inv (16) following treatment for germ cell tumor].
Tanabe, Kisa; Najima, Yuho; Inokuchi, Takuhiko; Endo, Mae; Nishio, Yuko; Sadato, Daichi; Kanbara, Yasuhiro; Atsuta, Yuya; Konuma, Ryosuke; Adachi, Hiroto; Wada, Atsushi; Kishida, Yuya; Uchibori, Yusuke; Noguchi, Yuma; Mukae, Junichi; Shingai, Naoki; Toya, Takashi; Shimizu, Noriaki; Kobayashi, Takeshi; Harada, Hironori; Sakamaki, Hisashi; Ohashi, Kazuteru; Harada, Yuka; Yamaguchi, Tatsuro; Akizuki, Nobuya; Doki, Noriko.
Afiliação
  • Tanabe K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Najima Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Inokuchi T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Endo M; Department of Psycho-oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Nishio Y; Department of Psycho-oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Sadato D; Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Kanbara Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Atsuta Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Konuma R; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Adachi H; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Wada A; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Kishida Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Uchibori Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Noguchi Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Mukae J; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Shingai N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Toya T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Shimizu N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Kobayashi T; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Harada H; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Sakamaki H; Laboratory of Oncology, Tokyo University of Pharmacy and Life Sciences.
  • Ohashi K; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Harada Y; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Yamaguchi T; Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Akizuki N; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
  • Doki N; Department of Psycho-oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital.
Rinsho Ketsueki ; 63(7): 746-752, 2022.
Article em Ja | MEDLINE | ID: mdl-35922942
A 22-year-old man with a history of mediastinal germ cell tumor, which was diagnosed at age 20 and remained disease-free after chemotherapy, was diagnosed with acute myeloid leukemia (AML) M2 in January 2020. Karyotype analysis of bone marrow (BM) specimen at diagnosis detected 47,XXY, inv (16) in all cells. Following induction treatment, he achieved complete remission with a remarkable decrease in the minimal residual disease marker. Although considered related to therapy, the AML had a prognostically favorable karyotype, and the initial treatment response was very good. He had no human leukocyte antigen-matched sibling donor candidate. Thus, allogeneic hematopoietic stem cell transplantation was not scheduled at the first complete remission. After three cycles of consolidation therapy, he remained disease-free for over one year. Karyotype analysis of BM during remission revealed that all analyzed cells harbored 47,XXY, and Klinefelter syndrome (KS) was diagnosed. Although the patient experienced an adjustment disorder on KS diagnosis, he had overcome the difficulty with the assistance of psycho-oncologists, clinical psychologists, and genetic counselors. Herein, we report this rare case of KS that manifested after AML diagnosis following mediastinal germ cell tumor treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Humans / Male Idioma: Ja Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Adult / Humans / Male Idioma: Ja Ano de publicação: 2022 Tipo de documento: Article